|
1
|
Lapshina MA, Shevtsova EF, Grigoriev VV, Aksinenko AY, Ustyugov AA, Steinberg DA, Maleev GV, Dubrovskaya ES, Goreva TV, Epishina TA, Zamoyski VL, Makhaeva GF, Fisenko VP, Veselov IM, Vinogradova DV, Bachurin SO. New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments. Molecules 2023; 28:7567. [PMID: 38005288 PMCID: PMC10673157 DOI: 10.3390/molecules28227567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/31/2023] [Accepted: 11/10/2023] [Indexed: 11/26/2023] Open
Abstract
Currently, there are no effective drugs for the treatment of amyotrophic lateral sclerosis (ALS). Only two drugs-edaravone and riluzole-have been approved, but they have very limited efficacy. The aim of this work was to modify the structural core of the Edaravone-phenylpyrazolone moiety and combine it with aminoadamantane pharmacophore in order to expand the spectrum of its action to a number of processes involved in the pathogenesis of ALS. New conjugates of edaravone derivatives with 1-aminoadamantanes combined with alkylene or hydroxypropylene spacers were synthesized, and their biological activity was investigated. Compounds were found that could inhibit lipid peroxidation and calcium-related mitochondrial permeability, block fast sodium currents of CNS neurons, and reduce aggregation of the mutated form of the FUS-protein typical to ALS. So, the proposed modification of the edaravone molecule has allowed the obtaining of new original structures that combine some prospective therapeutic mechanisms against key chains of the pathogenesis of ALS. The identified lead compounds can be used for further optimization and development of new promising drugs on this basis for the treatment of ALS.
Collapse
Affiliation(s)
- Maria A. Lapshina
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Elena F. Shevtsova
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Vladimir V. Grigoriev
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Aleksey Yu. Aksinenko
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Aleksey A. Ustyugov
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Daniil A. Steinberg
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Grigoriy V. Maleev
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Elena S. Dubrovskaya
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Tatiana V. Goreva
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Tatiana A. Epishina
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Vladimir L. Zamoyski
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Galina F. Makhaeva
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Vladimir P. Fisenko
- Department of Pharmacology, Sechenov I. M. First Moscow State Medical University, 8 Build. 2 Trubetskaya Str., 119991 Moscow, Russia;
| | - Ivan M. Veselov
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Daria V. Vinogradova
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| | - Sergey O. Bachurin
- Institute of Physiologically Active Compounds at the Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, 1 Severnij proezd, 142432 Chernogolovka, Russia; (M.A.L.); (E.F.S.); (V.V.G.); (A.Y.A.); (A.A.U.); (D.A.S.); (G.V.M.); (E.S.D.); (T.V.G.); (T.A.E.); (V.L.Z.); (G.F.M.); (I.M.V.); (D.V.V.)
| |
Collapse
|
|
2
|
Bronovitsky EV, Deikin AV, Ermolkevich TG, Elyakov AB, Fedorov EN, Sadchikova ER, Goldman IL, Ovchinnikov RK, Roman AY, Khritankova IV, Kukharsky MS, Buchman VL, Bachurin SO, Ustyugov AA. Gamma-carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis. DOKL BIOCHEM BIOPHYS 2015; 462:189-92. [PMID: 26163217 DOI: 10.1134/s1607672915030138] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Indexed: 11/23/2022]
Affiliation(s)
- E V Bronovitsky
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, Severnyi proezd 1, Chernogolovka, Moscow oblast, 142432, Russia,
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
3
|
Shelkovnikova TA, Robinson HK, Connor-Robson N, Buchman VL. Recruitment into stress granules prevents irreversible aggregation of FUS protein mislocalized to the cytoplasm. Cell Cycle 2013; 12:3194-202. [PMID: 24013423 PMCID: PMC3865015 DOI: 10.4161/cc.26241] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Fused in sarcoma (FUS) belongs to the group of RNA-binding proteins implicated as underlying factors in amyotrophic lateral sclerosis (ALS) and certain other neurodegenerative diseases. Multiple FUS gene mutations have been linked to hereditary forms, and aggregation of FUS protein is believed to play an important role in pathogenesis of these diseases. In cultured cells, FUS variants with disease-associated amino acid substitutions or short deletions affecting nuclear localization signal (NLS) and causing cytoplasmic mislocalization can be sequestered into stress granules (SGs). We demonstrated that disruption of motifs responsible for RNA recognition and binding not only prevents SG recruitment, but also dramatically increases the protein propensity to aggregate in the cell cytoplasm with formation of juxtanuclear structures displaying typical features of aggresomes. Functional RNA-binding domains from TAR DNA-binding protein of 43 kDa (TDP-43) fused to highly aggregation-prone C-terminally truncated FUS protein restored the ability to enter SGs and prevented aggregation of the chimeric protein. Truncated FUS was also able to trap endogenous FUS molecules in the cytoplasmic aggregates. Our data indicate that RNA binding and recruitment to SGs protect cytoplasmic FUS from aggregation, and loss of this protection may trigger its pathological aggregation in vivo.
Collapse
Affiliation(s)
- Tatyana A Shelkovnikova
- School of Biosciences; Cardiff University; Cardiff, UK; Institute of Physiologically Active Compounds Russian Academy of Sciences; Moscow Region, Russian Federation
| | | | | | | |
Collapse
|
|
4
|
van Blitterswijk M, Wang ET, Friedman BA, Keagle PJ, Lowe P, Leclerc AL, van den Berg LH, Housman DE, Veldink JH, Landers JE. Characterization of FUS mutations in amyotrophic lateral sclerosis using RNA-Seq. PLoS One 2013; 8:e60788. [PMID: 23577159 PMCID: PMC3620060 DOI: 10.1371/journal.pone.0060788] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Accepted: 03/02/2013] [Indexed: 12/13/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting in severe muscle weakness and eventual death by respiratory failure. Although little is known about its pathogenesis, mutations in fused in sarcoma/translated in liposarcoma (FUS) are causative for familial ALS. FUS is a multifunctional protein that is involved in many aspects of RNA processing. To elucidate the role of FUS in ALS, we overexpressed wild-type and two mutant forms of FUS in HEK-293T cells, as well as knocked-down FUS expression. This was followed by RNA-Seq to identify genes which displayed differential expression or altered splicing patterns. Pathway analysis revealed that overexpression of wild-type FUS regulates ribosomal genes, whereas knock-down of FUS additionally affects expression of spliceosome related genes. Furthermore, cells expressing mutant FUS displayed global transcription patterns more similar to cells overexpressing wild-type FUS than to the knock-down condition. This observation suggests that FUS mutants do not contribute to the pathogenesis of ALS through a loss-of-function. Finally, our results demonstrate that the R521G and R522G mutations display differences in their influence on transcription and splicing. Taken together, these results provide additional insights into the function of FUS and how mutations contribute to the development of ALS.
Collapse
Affiliation(s)
- Marka van Blitterswijk
- Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
- Department of Neurology, University of Massachusetts Medical Center, Worcester, Massachusetts, United States of America
| | - Eric T. Wang
- Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
- Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts, United States of America
| | - Brad A. Friedman
- Department of Molecular and Cell Biology, Harvard University, Cambridge, Massachusetts, United States of America
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | - Pamela J. Keagle
- Department of Neurology, University of Massachusetts Medical Center, Worcester, Massachusetts, United States of America
| | - Patrick Lowe
- Department of Neurology, University of Massachusetts Medical Center, Worcester, Massachusetts, United States of America
| | - Ashley Lyn Leclerc
- Department of Neurology, University of Massachusetts Medical Center, Worcester, Massachusetts, United States of America
| | - Leonard H. van den Berg
- Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
| | - David E. Housman
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America
| | - Jan H. Veldink
- Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
| | - John E. Landers
- Department of Neurology, University of Massachusetts Medical Center, Worcester, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|